Introduction
============

The cytochromes P450 or commonly known as CYPs P450, are of a superfamily of heme-binding enzymes with various physiological roles ([@b1-07mjms25042018_oa4]). The cytochrome P450 3A (*CYP3A4*) is believed to be the most predominant enzyme involved in metabolism of drugs used in clinical practice ([@b2-07mjms25042018_oa4]). A significant pool of data suggests that genetic variation in the *CYP3A4* gene results in functional changes that may significantly affect its activity leading to serious consequences for patients ([@b3-07mjms25042018_oa4], [@b4-07mjms25042018_oa4]).

*CYP3A4* plays a key role in the metabolism of important drugs used in breast cancer treatment which include anastrozole ([@b5-07mjms25042018_oa4]), letrozole ([@b6-07mjms25042018_oa4]), exemestane ([@b7-07mjms25042018_oa4]), tamoxifen ([@b8-07mjms25042018_oa4]), cyclophosphamide, paclitaxel and docetaxel ([@b9-07mjms25042018_oa4], [@b10-07mjms25042018_oa4]). Genetic polymorphism in the recently described *CYP3A4\*22* has been shown to influence the efficacy of tamoxifen in breast cancer patients ([@b11-07mjms25042018_oa4]). A similar study also reported that breast cancer patients harbouring *CYP3A4\*22* had lower tendency to develop of tamoxifen-associated hot flashes ([@b12-07mjms25042018_oa4]).

Based on the updated *CYP3A4* allele nomenclature database (<http://www.cypalleles.ki.se/cyp3a4.htm>) the wild type of *CYP3A4\*1* allele category consists of subtypes *CYP3A4\*1A-T* ([@b2-07mjms25042018_oa4]). With the exception of *CYP3A4\*22* and *CYP3A4\*18B* (which are located in the intron), *CYP3A4\*2* to *\*26* alleles are found in the exons and have been reported to cause changes in protein sequences. However, only some have been reported to affect the enzyme activity in vitro ([@b2-07mjms25042018_oa4]).

*CYP3A4\*4* (rs55951658) located on exon 5 was previously reported in three Chinese subjects \[*n* = 102\] ([@b13-07mjms25042018_oa4]). The single nucleotide polymorphisms (SNP) was associated with a functionally reduced activity of the *CYP3A4* enzyme resulting in a significant lipid-lowering effects of simvastatin in hyperlipidemic patients ([@b14-07mjms25042018_oa4]) and a profound impairment of *CYP3A4* activity on endocannabinoid anadamine metabolism in vitro ([@b15-07mjms25042018_oa4]).

*CYP3A4\*18B* (rs2242480) with a G\>A SNP located in intron 10 affects cyclosporine pharmacokinetics in Chinese renal transplant recipients ([@b16-07mjms25042018_oa4]). This finding was further confirmed in healthy Chinese volunteers more recently ([@b17-07mjms25042018_oa4]). These findings suggest that *CYP3A4\*18B* is associated with increased *CYP3A4* activity and may play a significant role in the inter-individual variability observed in cyclosporine pharmacokinetics.

*CYP3A4\*22* (rs35599367) with a C\>T SNP located in intron 6 was recently discovered ([@b18-07mjms25042018_oa4]) and has since been established as a potentially important biomarker in drug discovery and development. The reported frequencies in Caucasians and Asians/Africans are 0.08 and 0.04, respectively ([@b2-07mjms25042018_oa4]). The presence of *CYP3A4\*22T*-allele was further reported to be associated with midazolam clearance in renal allograft patients, indicating that there is a reduced in vivo activity of *CYP3A4* in individuals with T variant of *CYP3A4\*22* ([@b19-07mjms25042018_oa4]).

Inter-individual variability in drugs metabolism influences their therapeutic levels and constitutes a major concern during drug discovery and development. As highlighted above, impairment of *CYP3A4* enzyme activity due to the presence of *CYP3A4\*4*, *\*18B* and *\*22* play a significant role in this variation. This fact necessitates the need for novel therapeutic approaches geared towards improving cure rates and minimising adverse drug reactions which could be achieved by the identification of these genetic biomarkers through various pharmacogenetic studies aimed at personalised therapies. To achieve the primary goal of personalised medicine, simple, robust, fast and inexpensive methods for detection of *CYP3A4* SNPs are necessary. We report for the first time, a novel multiplex polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) method for simultaneous detection of *CYP3A4\*4 A\>G*, *CYP3A4\*18B G\>A* and *CYP3A4\*22 C\>T* alleles.

Materials and Methods
=====================

Study Population and Sample Collection
--------------------------------------

This was a prospective study among post-menopausal women (aged between 44 and 83 years) with estrogen receptor positive breast cancer who attended the Oncology Clinic, Universiti Sains Malaysia, Kelantan, Malaysia. The protocol was approved by the Human Research Ethical Committee of the Universiti Sains Malaysia (USMKK/PPP/JEPeM \[260.3.([@b21-07mjms25042018_oa4])\]) which complied with the Declaration of Helsinki. The subjects were post-menopausal women \[*n* = 94\] with histologically confirmed hormone receptor positive stages I to III breast cancer based on the American Joint Committee on Cancer (AJCC) staging manual (sixth edition). Following the screening of the medical records, the patients were approached for study enrollment at their regular follow-up appointments. Only patients who signed written informed consents were enrolled and were then asked to complete an individual case report form. Peripheral blood (1 mL) was collected for genomic DNA extraction. The whole blood was stored in EDTA (BD Franklin Lakes, NJ USA) at −20 °C until use.

Polymerase Chain Reaction (PCR) Method
--------------------------------------

Genomic DNA was extracted from whole blood using QIAamp® DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. DNA concentration and purity were determined using Infinite® 200 NanoQuant (Tecan, Switzerland). DNA pellet was dissolved in 100 μL of TE buffer (approximately 20 ng/μL DNA concentration) and was stored at −20 °C until use.

The multiplex PCR method was developed in accordance with QIAGEN^®^ Multiplex PCR Handbook ([@b20-07mjms25042018_oa4]) using QIAGEN^®^ Multiplex PCR Plus Kit. A uniplex PCR method was first conducted to determine the specificity, functionality and annealing temperature of each primer set.

Primer Design
-------------

The primer for amplification of *CYP3A4\*22* was designed using primer 3 software, version 4.0.0 (<http://bioinfo.ut.ee/primer3/>) ([@b21-07mjms25042018_oa4]). The primer for the amplification of *CYP3A4\*4* was adopted from our previous study ([@b22-07mjms25042018_oa4]) while the primer for *CYP3A4\*18B* amplification was modified from ([@b23-07mjms25042018_oa4]). Prior to use, the primer specificity was checked using the "BLAST" database at <http://blast.ncbi.nlm.nih.gov/Blast.cgi>. The primer sequences are shown in [Table 1](#t1-07mjms25042018_oa4){ref-type="table"}.

Hypothetical RFLP Results
-------------------------

The hypothetical sizes of restriction fragment length polymorphism (RFLP) for *CYP3A4\*4, CYP3A4\*18B* and *CYP3A4\*22* were investigated using BioEdit v7.2.5 software (<http://www.mbio.ncsu.edu/bioedit/bioedit.html>) and are depicted in [Table 2](#t2-07mjms25042018_oa4){ref-type="table"}.

Multiplex PCR Reaction Set Up and Cycling Protocol
--------------------------------------------------

A total of 50 μL PCR reaction was prepared. The mixture consisted of 1× Multiplex PCR Master mix (QIAGEN^®^) containing HotStar^®^ DNA Polymerase, Multiplex PCR buffer (6 mM MgCl~2~, pH 8.7) and dNTP mix; 0.2 μM of forward and reverse primers for each SNP (\*4_F, \*4_R, \*18B_F, \*18B_R, \*22_F, and \*22_R), 100 ng of DNA template and double distilled water. Three samples previously confirmed by sequencing were used as positive controls in the PCR and RFLP for each of the SNP. A negative control without DNA template in the reaction mix was set up.

The cycling protocol consisted of an initial PCR activation step for 5 min at 95 °C, followed by 35 cycles of 30 s at 95 °C, 90 s at 61.9 °C and 90 s at 72 °C and a 10 min of final extension at 68 °C.

Endonuclease Restriction Assay-RFLP Method
------------------------------------------

Prior to the RFLP, the multiplex PCR product was separated into three tubes for the genotyping of *CYP3A4\*4, CYP3A4\*18B* and *CYP3A4\*22* using *BsmAI* (NEB® Inc, Massachusetts, USA), *RsaI* (NEB® Inc, Massachusetts, USA) and *BseYI* (NEB® Inc, Massachusetts, USA) restriction enzymes (RE), respectively. The first tube contained 2.0 U *BsmAI*, 1× CutSmart NEBuffer^®^ (NEB® Inc, Massachusetts, USA), 0.3--0.4 μg of PCR products and 9.2 μL doubly distilled water followed by incubation at 55 °C for 60 min. (Alpha Innotech, USA). The second tube contained 4.0 U of *RsaI*, 1× CutSmart NEBuffer^®^ (NEB® Inc, Massachusetts, USA), 0.3--0.4 μg fresh PCR products and 8.8 doubly distilled water, followed by incubation at 37 °C for 60 min. The third tube contained 6.0 U *BseYI*, 1× NEBuffer 3.1^®^ (NEB® Inc, Massachusetts, USA), 0.3--0.4 μg fresh PCR template and 8.4 μL doubly distilled water; incubated at 37 °C for 60 min followed by an inactivation step at 80 °C for 20 min. The incubation for all RFLP samples was carried out using an Accublock Digital Dry Bath.

Agarose Gel Electrophoresis
---------------------------

High resolution blend agarose 3:1 HRB^TM^ gels (AMRESCO^®^, Ohio, USA) (2% and 4%) were prepared and immersed into electrophoresis gel tank containing 1× Tris-Borate-EDTA (TBE) buffer (AMRESCO^®^, Ohio, USA). For confirmation of uniplex and multiplex PCR ([Figure 1](#f1-07mjms25042018_oa4){ref-type="fig"}), 1.0 μL of 6× DNA loading dye^®^ (Thermo Fisher Scientific Inc, Massachusetts, USA) was mixed with 1.0 μL of SYBR^®^ Green I stain (Lonza, Rockland, USA) and either 2.0 μL of a Quick-Load 100bp DNA ladder (NEB® Inc, Massachusetts, USA) or 2.0 μL of the PCR products on a Parafilm^®^ (Parafilm, Bemis, USA); the mixture was then loaded into the well and then electrophoresed on 2% agarose at 100 V for 45 min.

On the other hand, for multiplex PCRRFLP ([Figure 2](#f2-07mjms25042018_oa4){ref-type="fig"}), 1.0 μL of 6× DNA loading dye^®^ (Thermo Fisher Scientific Inc, Massachusetts, USA) was mixed with 1.0 μL of SYBR^®^ Green I stain (Lonza, Rockland, USA) and either 1.0 μL of a 50 bp DNA ladder (NEB® Inc, Massachusetts, USA) or 2.0 μL of PCR products on a Parafilm^®^ (Parafilm, Bemis, USA); the mixture was then loaded into a 4% agarose and electrophoresed at 100 V for 1.5 h.

All gels were visualised using Alpha Innotech^®^ Ultraviolet Transilluminator (Alpha Innotech^®^ USA).

PCR Products Purification and DNA Sequencing
--------------------------------------------

Prior to sequencing, the PCR products were purified using illustra^TM^ ExoProster^TM^ 1-Step Enzymatic and Sequencing Clean-Up (GE HealthCare Life Sciences, UK) according to manufacturer's instructions.

SNP Analysis
------------

In order to validate our method, control samples' nucleotide sequences were run through the snpBLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch>) and were compared against the SNP database (<http://www.ensembl.org/index.html>) where each SNP was identified by its reference SNP (rs) ID. For instance, rs55951658, rs2242480, and rs35599367 are the rs numbers for *CYP3A4\*4, CYP3A4\*18B* and *CYP3A4\*22*, respectively.

Results
=======

In the present study, the developed multiplex PCR-RFLP method was used to successfully genotype a total of 94 patients simultaneously. The method was validated by sequencing of selected DNA samples using random sampling method (*n* = 38). For further confirmation, samples with known genotypes were run using a uniplex PCR method and the results obtained showed 100% concordance with the multiplex PCR technique ([Figure 1](#f1-07mjms25042018_oa4){ref-type="fig"}) i.e. 244 bp, 331 bp and 793 bp for *CYP3A4\*4*, *CYP3A4\*18B* and *CYP3A4\*22*, respectively.

A summary of the PCR-RFLP product sizes, endonuclease used and sizes of fragments following digestion is shown in [Table 2](#t2-07mjms25042018_oa4){ref-type="table"}.

Amplification of CYP3A4\*4, CYP3A4\*18B and CYP3A4\*22 and Their Digestions
---------------------------------------------------------------------------

The length of the PCR product for *CYP3A4\*4* was 244 bp ([Figure 1](#f1-07mjms25042018_oa4){ref-type="fig"}). [Figure 2](#f2-07mjms25042018_oa4){ref-type="fig"} depicts the *BsmAI* digestion of *CYP3A4\*4* which yielded 15 bp (not shown), 88 bp and 141 bp for the wild type, however, no variant alleles were detected for this gene in all the 94 study subjects. In addition, the *BsmAI* also recognised the sequence *5\'\...G T C T C (N)~1~*↓*\...3\'* in *CYP3A4\*22* and therefore digested it to give rise to 56 bp and 59 bp (not shown), 153 bp and 525 bp. Nevertheless, the *CYP3A4\*18B* sequence (331 bp) was unaffected by the action of *BsmAI* ([Table 2](#t2-07mjms25042018_oa4){ref-type="table"} and [Figure 2](#f2-07mjms25042018_oa4){ref-type="fig"}).

The length of the PCR product for *CYP3A4\*18B* was 331 bp ([Figure 1](#f1-07mjms25042018_oa4){ref-type="fig"}) and its digestion with *RsaI* is depicted in [Figure 2](#f2-07mjms25042018_oa4){ref-type="fig"}. The *RsaI* recognises the sequence 5*\'*...G T ↓ A C ...3*\'* and therefore the wild type *CYP3A4\*18B* (115 bp and 216 bp) could be easily differentiated from the homozygous (undigested 331 bp) and heterozygous variants (115 bp, 216 bp and 331 bp). The *RsaI* also recognised the sequence 5*\'*...G T ↓ A C ...3*\'* in *CYP3A4\*22* sequence and therefore yielded two band sizes of 112 bp and 681 bp. The CYP3A4\*4 sequence (244 bp) was unaffected by the action of *RsaI* ([Table 2](#t2-07mjms25042018_oa4){ref-type="table"} and [Figure 2](#f2-07mjms25042018_oa4){ref-type="fig"}).

The length of *CYP3A4\*22* PCR product was 793 bp ([Figure 1](#f1-07mjms25042018_oa4){ref-type="fig"}) and its 5*\'*...C ↓ C C A G C ...3*\'* sequence was recognised by *BseYI* which makes it easy to differentiate the wild (219 bp and 575 bp) from the variant types. However, in this study, no variant alleles of *CYP3A4\*22* were detected. The *CYP3A4\*4* (244 bp) and *CYP3A4\*18B* (331 bp) sequences were unaffected by the digestion with *BseYI* ([Table 2](#t2-07mjms25042018_oa4){ref-type="table"} and [Figure 2](#f2-07mjms25042018_oa4){ref-type="fig"}).

The chromatograms of *5\'\...G T C T C (N)~1~*↓ *\...3\'* for *CYP3A4\*4* ([Figure 3](#f3-07mjms25042018_oa4){ref-type="fig"})*, 5\'...G T* ↓ *A C ...3\'* for *CYP3A4\*18B* \[[Figures 4(a), 4(b) and 4(c)](#f4-07mjms25042018_oa4){ref-type="fig"}\] and 5*\'*...C ↓ C C A G C ...3*\'* for *CYP3A4\*22* ([Figure 5](#f5-07mjms25042018_oa4){ref-type="fig"}) sequences were confirmed using a BioEdit v7.2.5 software and the sequencing results matched those of the PCR-RFLP and snpBLAST analyses.

Discussion
==========

Our study is the first to simultaneously determine the genotype of *CYP3A4\*4 A\>G*, *CYP3A4\*18B* G\>A and *CYP3A4\*22 C\>T* that may be useful as possible biomarkers to predict breast cancer response to treatment.

The newly developed method is stable and reproducible to be conducted in only a single-tube multiplex reaction. The method was successfully applied in genotyping of 94 subjects with a significantly minimised pre-PCR optimisation step and thermal cycling time when compared to conventional single reaction in multiple PCR tubes.

In this method, optimisation of PCR components such as MgCl~2~, dNTPs and Taq DNA polymerase was not required because the multiplex PCR master mix that was used contained pre-optimised concentrations of HotStar Taq DNA polymerase and MgCl~2~ plus dNTPs. Moreover, the multiplex PCR buffer contained a novel synthetic factor MP which enhances primer annealing and extension regardless of primer sequences. The use of a ready-made mastermix greatly reduced the time to set up the reaction while enhancing the reproducibility of the method by eliminating a variety of potential sources of pipetting errors ([@b20-07mjms25042018_oa4]).

Another critical step for a successful multiplex PCR method is primer design. There is a relationship between the primer size, its annealing temperature (T~a~) and hybridisation stability ([@b20-07mjms25042018_oa4]). Furthermore, the rule of thumb for optimum primer length is 18--30 nucleotides ([@b24-07mjms25042018_oa4]). In the present method, the length of all the primers ranged between 23--25 bases ([Table 1](#t1-07mjms25042018_oa4){ref-type="table"}). The melting temperature (T~m~) of a primer is the key factor in DNA-DNA hybrid stability and is important in the optimisation of a primer T~a~. In general, extremely low T~a~ can result in significant primer mispairing and the formation of multiple nonspecific bands, whereas high T~a~ may lead to the formation of insufficient primer-template hybridisation with subsequent reduction in the PCR product yield. Since the T~m~ of a primer is also related to its GC content which in turn provides information about the primers annealing stability or strength, it is recommended that each primer should have a GC content of 40%--60% ([@b25-07mjms25042018_oa4]). The present method was developed based on some of these well-established recommendations.

The use of separate tubes for the identification of *CYP3A4\*4 A\>G*, *CYP3A4\*18B* G\>A and *CYP3A4\*22 C\>T* SNPs by *BsmAI*, *RsaI,* and *BseYI,* respectively was to ensure that errors in terms of double digestion or the formation of nonspecific bands were minimised. As observed in [Table 2](#t2-07mjms25042018_oa4){ref-type="table"} and [Figure 2](#f2-07mjms25042018_oa4){ref-type="fig"}, both *BsmAI* and *RsaI* have the ability to digest the *CYP3A4\*22* sequence in addition to their primary targets (*CYP3A4\*4* and *CYP3A4\*18B* sequences, respectively) which was unavoidable due to the long sequence of the *CYP3A4\*22* PCR product.

A high percentage (4%) high resolution agarose was used because of its ability to discriminate small nucleic acid fragments. Additionally the use of less-hazardous methods such as high resolution agarose is preferred over polyacrylamide which is hazardous to the central nervous system ([@b26-07mjms25042018_oa4]). Furthermore, the conventional elecptrophoresis technique involving the use of agarose gel is cost effective and is readily available for routine laboratory application.

The present method was successfully applied in the genotyping of a total of 94 breast cancer patients. Randomly selected DNA samples were sent for sequencing in order to further validate the findings. However, sequencing is believed to be more reliable than the conventional uniplex PCR-RFLP for genotyping of DNA samples ([@b26-07mjms25042018_oa4]).

A simple, rapid multiplex PCR-RFLP method will help in routine simultaneous identification of SNPs and determination of allelic and genotypic frequencies of *CYP3A4\*4*, *CYP3A4\*18B* and *CYP3A4\*22* which can be applied in various pharmacogenetics studies to predict patients' responses to treatment and serve as a basis for personalised treatment of breast cancer as well as in many other diseases.

Limitation of Study
===================

The limitation of this method is that only three out of the many *CYP3A4* SNPs were simultaneously detected which was mainly due to difficulty in finding a RE that is only specific to only one sequence in each allele.

Future Study
============

A multiplex method capable of simultaneous detection of more CYP3A4 SNPs is suggested in future.

Conclusion
==========

A simple, rapid, cost-effective and reproducible method has been successfully established for routine applications in identification of SNPs and determination of allelic and genotypic frequencies. The method does not require special equipment and requires only a small amount of standard PCR reagents.
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![A 2% agarose gel showing PCR products from multiplex and uniplex PCR for *CYP3A4\*4*, *CYP3A4\*18B* and *CYP3A4\*22*. L1: Quick-Load 100bp DNA ladder (NEB® inc, Massachusetts, USA). L2: multiplex pcr with band sizes of 244 bp, 331 bp and 793 bp. L3, L4 and L5 contain positive controls for *CYP3A4\*4* with 244 bp, *CYP3A4\*18B* with 331 bp and *CYP3A4\*22* with 793 bp respectively. L6 is a negative control](07mjms25042018_oa4f1){#f1-07mjms25042018_oa4}

![A 4% agarose gel of multiplex PCR-RFLP analysis of *CYP3A4\*4*, *CYP3A4\*18B* and *CYP3A4\*22*. L1 contained GeneRuler 50bp DNA ladder (Thermo Fisher Scientific Inc, Massachusetts, USA). L2 contained wild type *CYP3A4\*4* allele (88 bp, and 141 bp) together with 331 bp for *CYP3A4\*18B* and 153 bp and 525 bp from *CYP3A4\*22* digestions. L3, L4 and L5 contain wild type (216 bp and 115 bp), homozygous (undigested 331 bp) and heterozygous (115 bp, 216 bp and 331 bp) variants, respectively for *CYP3A4\*18B*. They also contain 112 bp (except for L4 in which it is not shown) and 681 bp from *CYP3A4\*22* as well as 244 bp for *CYP3A4\*4*. L6 contained wild type *CYP3A4\*22* (219 bp and 574 bp) as well as 244 bp and 331 bp for *CYP3A4\*4* and *CYP3A4\*18B,* respectively. L6 contained negative control](07mjms25042018_oa4f2){#f2-07mjms25042018_oa4}

![Sequencing results confirming the presence of wild type *CYP3A4\*4 A\>G* (presence of the "A" nucleotide only). The highlighted "A" is adenine indicating the absence of *CYP3A4\*4* SNP in this subject](07mjms25042018_oa4f3){#f3-07mjms25042018_oa4}

![Sequencing results showing the presence of (a) wild type of *CYP3A4\*18B G\>A*; (b) homozygous variant of *CYP3A4\*18B G\>A*; (c) heterozygous variant of *CYP3A4\*18B G\>A*](07mjms25042018_oa4f4){#f4-07mjms25042018_oa4}

![Sequencing results confirming the presence of wild type *CYP3A4\*22 C\>T* (presence of the "C" nucleotide only). The highlighted "C" is cytosine indicating the absence of *CYP3A4\*22* SNP in this subject](07mjms25042018_oa4f5){#f5-07mjms25042018_oa4}

###### 

Primer sequences for SNPs genotyping

  SNPs               Primers                     Sequences (5' 3')           Length (bp)   T~m~ (°C)   GC (%)                        References
  ------------------ --------------------------- --------------------------- ------------- ----------- ----------------------------- -----------------------------
  CYP3A4\*4 A\>G     \*4_F                       CACATTTTCTACAACCATGGAGACC   25            72          44.0                          ([@b22-07mjms25042018_oa4])
  \*4_R              TACCTGTCCCCACCAGATTCATTCT   25                          74            48.0        ([@b22-07mjms25042018_oa4])   
  CYP3A4\*18B G\>A   \*18B_F                     CCACGAGCAGTGTTCTCTCCTTC     23            72          56.5                          Self-designed
  \*18B_R            AATAGAAAGCAGATGAACCAGAGCC   25                          72            44.0        ([@b23-07mjms25042018_oa4])   
  CYP3A4\*22 C\>T    \*22_F                      GCATAGAGTCTGCAGTCAGGCAAT    24            70          47.8                          Self-designed
  \*22_R             GATGACAGGGTTTGTGACAGGGG     23                          72            56.5        Self-designed                 

###### 

Hypothetical RFLP lengths for *CYP3A4\*4, CYP3A4\*18B* and *CYP3A4\*22* following digestion with *BsmAI*, *RsaI* and *BseYI*, respectively

  SNPs                PCR sizes   RE and the recognition sites       REs tested   Frequencies   Fragments (bp)
  ------------------- ----------- ---------------------------------- ------------ ------------- ------------------
  ***CYP3A4\*4***     244         BsmAI                                                         
  Wild type                       5\'\...G T C T C (N)~1~↓\...3\'    *BsmAI*      2             15, 88, 141
                                  3\'\...C A G A G (N)~5~↑ \...5\'   *RsaI*       ND            331
                                                                     *BseYI*      ND            793
  Mutant                                                             *BsmAI*      3             15, 47, 88, 94
                                                                     *RsaI*       ND            331
                                                                     *BseYI*      ND            793
                                                                                                
  ***CYP3A4\*18B***   331         *RsaI*                                                        
  Wild type                       5\'...G T ↓ A C ...3\'             *RsaI*       1             115, 216
                                  3\'...C A ↑ T G ...5\'             *BsmAI*      ND            244
                                                                     *BseYI*      ND            793
  Mutant                                                             RsaI         ND            331
                                                                     *BsmAI*      ND            244
                                                                     *BseYI*      ND            793
                                                                                                
  ***CYP3A4\*22***    793         *BseYI*                                                       
  Wild type                       5\'...C ↓ C C A G C ...3\'         *BseYI*      1             219, 574
                                  3\' ...G G G T C ↑ G ...5\'        *BsmAI*      3             56, 59, 153, 525
                                                                     *RsaI*       1             112, 618
  Mutant                                                             *BseYI*      ND            793
                                                                     *BsmAI*      3             56, 59, 153, 525
                                                                     *RsaI*       1             112, 681

ND: no digestion
